Key result
Telcagepant causes no contraction in isolated human coronary arteries, unlike zolmitriptan.
Why the study?
The vascular effects and coronary vasoconstrictive potential of the CGRP receptor antagonist telcagepant compared to zolmitriptan were not well characterized in human coronary arteries.
Does telcagepant cause less coronary vasoconstriction compared to zolmitriptan in human isolated coronary arteries?
Population
Human isolated coronary arteries
Comparison
Telcagepant (up to 30 microM) vs zolmitriptan (1 to 10 microM)
Design
Preclinical experimental study
Authors
Loading...
May warrant investigation of CGRP antagonists in migraine patients with cardiovascular disease; leaves open confirmation in clinical settings.
Does telcagepant cause less coronary vasoconstriction compared to zolmitriptan in human isolated coronary arteries?
Telcagepant, a CGRP receptor antagonist, does not cause coronary vasoconstriction in human isolated coronary arteries, unlike zolmitriptan, suggesting a safer cardiovascular profile for migraine treatment.
Lynch et al. (2010) studied Migraine. Telcagepant (MK-0974) vs. Zolmitriptan was evaluated on Change in contractile tone. Telcagepant at concentrations up to 30 microM evoked no change in contractile tone in human isolated coronary arteries, whereas zolmitriptan caused a concentration-dependent contraction.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: